Enzo Biochem, Inc. announced its Enzo Clinical Labs unit has entered into a collaboration with Italy-based DiaSorin, a company focusing on the field of biotechnologies, that will enable the Lab to provide physician-clients in metropolitan New York with diagnostic tools and will also serve to evaluate new DiaSorin offerings in the future.
"Our agreement with DiaSorin has multiple benefits that, in addition to providing additional cutting edge diagnostic technology to physicians and their patients from a global leader in the in vitro diagnostics field, also reflects an acknowledgement of the excellent and expanding capabilities of our Lab, a center of excellence, in evolving medical science," said Barry Weiner, Enzo President.
According to a release, as part of the agreement, Enzo Clinical Labs has added two new DiaSorin LIAISON XL Analyzers, a new high throughput, chemiluminescent, random access analyzer that provides a menu of over 30 assays. The system requires no daily maintenance with most tests and can manage up to 25 different assays on board.
"We are excited to collaborate with Enzo to provide high quality automated testing solutions to best serve their clients with an opportunity for growth and improved patient care," said John Eskdale, DiaSorin President. "The LIAISON XL, with its expanded menu, will offer Enzo a competitive advantage in the areas of specialty testing which include infectious disease, growth, hypertension, and bone & mineral."
((Comments on this story may be sent to email@example.com))